Skip to content
Peptigraph home

Eloralintide Phase 2 trial (NCT06230523)

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
263
actual
Start
5 Feb 2024 (actual)
Primary completion
30 May 2025 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT06230523 study arms
ArmTypeInterventionsDescription
PlaceboPlacebo comparatorDrug: PlaceboParticipants received subcutaneous (SC) injections of eloralintide-matching placebo administered once weekly (QW) for 48 weeks.
1 mg EloralintideExperimentalDrug: EloralintideParticipants received eloralintide 1 milligram (mg) SC QW for 48 weeks.
3 mg EloralintideExperimentalDrug: EloralintideParticipants received eloralintide 3 mg SC QW for 48 weeks.
6 mg EloralintideExperimentalDrug: EloralintideParticipants received eloralintide 6 mg SC QW for 48 weeks.
9 mg EloralintideExperimentalDrug: EloralintideParticipants received eloralintide 9 mg SC QW for 48 weeks.
6/9 mg EloralintideExperimentalDrug: EloralintideParticipants received eloralintide 6 mg SC QW for 20 weeks, followed by eloralintide 9 mg SC QW for 28 weeks, for a total treatment duration of 48 weeks.
3/6/9 mg EloralintideExperimentalDrug: EloralintideParticipants received eloralintide 3 mg SC QW for 4 weeks, followed by eloralintide 6 mg SC QW for 4 weeks, followed by eloralintide 9 mg SC QW for 40 weeks, for a total treatment duration of 48 weeks.
Endpoints

Primary endpoint

NCT06230523 primary outcomes
MeasureTime frame
Percent Change From Baseline in Body Weight at Week 48Baseline, Week 48
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06230523 secondary outcomes
MeasureTime frame
Change From Baseline in Body Weight at Week 48Baseline, Week 48
Mean Percentage of Participants Who Achieved Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline to Week 48Baseline to Week 48
Mean Percentage of Participants Who Achieved ≥ 10% Body Weight Reduction From Baseline to Week 48Baseline to Week 48
Change From Baseline in Body Mass Index (BMI) at Week 48Baseline, Week 48
Pharmacokinetics (PK): Area Under the Curve (AUC) of Eloralintide at Steady StatePredose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48
PK: Maximum Concentration (Cmax) of Eloralintide at Steady StatePredose at Week 0, Week 4, Week 8, Week 12, Week 24, Week 36; Post dose (2 to 6 hours after dosing) at Week 0, Week 24; Post dose (24 to 72 hours after dosing) at Week 12; random at Week 48
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT06230523.

Week 48 weight change posted for each eloralintide group

The posted primary outcome is the percent change from baseline in body weight at week 48.[1]

Outcome group OG004 is labelled 9 mg Eloralintide.[1]

The placebo group posted a least-squares mean change of -0.4%, with a spread of 0.91.[1]

Outcome group OG004 posted a least-squares mean change of -20.1%, with a spread of 1.31.[1]

Sources

  1. 1A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.